Trial Profile
Study of evaluating T cells subsets and cytokines in Phase II clinical trial of Tamibarotene (AM80G) for chronic graft-versus-host disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Tamibarotene (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacodynamics
- 20 May 2016 New trial record